Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1426]

Synthetic lethality as a basis to select drug combinations

Prof René Bernards - Netherlands Cancer Institute, Amsterdam, Holland

Synthetic lethality as a basis to select drug combinations ( Prof René Bernards - Netherlands Cancer Institute, Amsterdam, Holland )

Patient-specific peptide vaccines

Prof Hans-Georg Rammensee - University of Tübingen, Tübingen, Germany

Patient-specific peptide vaccines ( Prof Hans-Georg Rammensee - University of Tübingen, Tübingen, Germany )

Proteogenomics in cancer research

Dr Henry Rodriguez - National Cancer Institute (NIH), Bethesda, USA

Proteogenomics in cancer research ( Dr Henry Rodriguez - National Cancer Institute (NIH), Bethesda, USA )

Novel models to personalise cancer therapeutics

Dr Olli Kallioniemi - Karolinska Institutet, Stockholm, Sweden

Novel models to personalise cancer therapeutics ( Dr Olli Kallioniemi - Karolinska Institutet, Stockholm, Sweden )

Benefits of skin and nipple saving mastectomy

Prof Anurag Srivastava - All India Institute of Medical Sciences, New Delhi...

Benefits of skin and nipple saving mastectomy ( Prof Anurag Srivastava - All India Institute of Medical Sciences, New Delhi, India )

Low dose exemestane usage in breast cancer

Dr Davide Serrano - European Institute of Oncology, Milan, Italy

Low dose exemestane usage in breast cancer ( Dr Davide Serrano - European Institute of Oncology, Milan, Italy )

BRCA1 and BRCA2 genes and hereditary breast cancers

Dr Judy Garber - Dana-Farber Cancer Institute, Boston, USA

BRCA1 and BRCA2 genes and hereditary breast cancers ( Dr Judy Garber - Dana-Farber Cancer Institute, Boston, USA )

The Umberto Veronesi Milan Breast Cancer Conference

Dr Paolo Veronesi - European Institute of Oncology, Milan, Italy

The Umberto Veronesi Milan Breast Cancer Conference ( Dr Paolo Veronesi - European Institute of Oncology, Milan, Italy )

4 years of RESONATE data for CLL patients treated with ibrutinib

Dr Carolina Moreno Atanasio - Hospital de la Santa Creu i Sant Pau, Barcelona...

4 years of RESONATE data for CLL patients treated with ibrutinib ( Dr Carolina Moreno Atanasio - Hospital de la Santa Creu i Sant Pau, Barcelona, Spain )

Hemcare - multiple myeloma learning programme

Erik Aerts - President of HNHCP, Winterthur, Switzerland

Hemcare - multiple myeloma learning programme ( Erik Aerts - President of HNHCP, Winterthur, Switzerland )

Enasidenib in mIDH relapsed and refractory AML

Dr Eytan Stein - Memorial Sloan Kettering Cancer Center, New York, USA

$Enasidenib in mIDH relapsed and refractory AML ( Dr Eytan Stein - Memorial Sloan Kettering Cancer Center, New York, USA )$

Safety and efficacy of blinatumomab for acute lymphoblastic leukaemia

Dr Max Topp - University of Wurzburg, Wurzburg, Germany

Safety and efficacy of blinatumomab for acute lymphoblastic leukaemia ( Dr Max Topp - University of Wurzburg, Wurzburg, Germany )

More from ecancer